Krintafel Tablet, Film Coated
Product Images NDC 0173-0889

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Krintafel (NDC 0173-0889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tafenoquine Chemical Structure Clean (Krintafel Spl Graphic 01)

Chemical structure of tafenoquine succinate, the active ingredient in Krintafel tablets, showing molecular components and bonds.*

FDA Label Image

Krintafel 150 mg 30 Count Label (Krintafel Spl Graphic 02)

Krintafel 150 mg film-coated tablets packaging label shows tafenoquine as the active ingredient. It indicates a prescription-only oral tablet with a one-time dose of 2 tablets. The label includes a warning for glucose-6-phosphate dehydrogenase deficiency testing before use and storage instructions at controlled room temperature. Labeler is GlaxoSmithKline LLC. The product is made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.